Client News

Pentixapharm Acquires Target Discovery Business of Glycotope

Mainz Biomed Provides Half Year 2024 Corporate Update

Pentixapharm Announces Expansion of Supervisory Board with the Appointment of Distinguished Endocrinologist Marcus Quinkler

Formycon Receives FDA Approval for FYB203/ AHZANTIVE® (aflibercept-mrbb), a Biosimilar to Eylea®

iOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer

CARBIOS and Zhink Group Enter Official Discussions for Long-Term Partnership to Build PET Biorecycling Industrial Capacities in China in View of First Licensing Agreement for 50k Tons per Year

Newron Pharmaceuticals Reports on its 2024 Investor Day in New York City

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

Medigene AG Reports Results of Annual General Meeting

InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)